THTX - Earnings call transcript Q1 2022

Due to licensing restrictions, you must log in to view earnings call transcripts.

Operator

Good morning, ladies and gentlemen, and thank you for standing by. Welcome to Theratechnologies First Quarter Fiscal Year 2022 Earnings Conference Call. [Operator Instructions]. I would like to remind everyone that this conference call is being recorded today, Wednesday April 13, 2022, at 8:30 a.m. Eastern Time. the to turn Advisors. Mullaly, now will call John over LifeSci I Mr. please ahead. Mullaly, go

John Mullaly

and Levesque, Senior Thank Executive Mr. be welcome. you, Paul today's on Theratechnologies; Chief Officer, call. Mr. the and speakers Officer President and Philippe President Dubuc, Vice Financial will of Chief and

to the update has to in also Officer, the Marsolais, company’s call, asset. today’s progress Chief Christian Theratechnologies on to THXXXX, lead regard oncology Additionally, Medical of asked participate provide an

asked everyone or made those begins by message forward-looking Paul remarks, preparing remarks and his assumptions by developments. statements, several expectations intentions, results, actually current the Theratechnologies, that differ by I have forward-looking been future today its to materially In from before statements. following and Theratechnologies achievements, Now, regarding of would levels I read performance, like that events contain goals these statements. were forward-looking activity, there about plans, company will obtained to or results statements are remind and the risks future or Theratechnologies' other

a investors section discussion guarantee analysis Theratechnologies forward-looking on current and issued potential morning www.sec.gov. will materialize, Sedar on forward-looking the not that are management undue refers the cannot cautioned As statement you them. to at on available at and any in place company its information EDGAR to consequence, reliance or this and www.sedar.com

call I expectations Paul. securities Theratechnologies' April would otherwise. a turn as forward-looking any XX, information, of as of future represent any as does to conference law, to to like Theratechnologies events, result by statements not be whether Forward-looking the statement XXXX. update required now over obligation Except may or new undertake

Paul Levesque

good everyone and today. call joining John the to morning Thanks,

reporting year, solid to into well great and and off are We the start. a new

our a model Officer, today, a brief development we business. annual advantages Medical both been commercial a business where but we of our are which American to have As drug during have strategic Theratechnologies' you confident year-end note, presented recent join our than tell asked On today excitement more studies Christian we Research of order took consisting the in leaning never history into for place fully in THXXXX from significance Association this Chief this call, year's pipeline the of and to Cancer our can on at call meeting, earlier this important the update new preclinical as Marsolais, provide week. the

Our representing new cancers with refractory, solid, oncology, and asset, range are across promising significant patient where pipeline opportunities needs. across a commercial our conjugate for metastatic we a lead unmet technology, drug exploring potentially peptide broad is of

square Our Phase used X regimen, we times and THXXXX, are progressing per well XXX-milligram dose dose. conclusion study in agent indicated therapeutic the have trial, our for the X meter well-established lead well-characterized the in nearing of and the few X.X equivalent linked peptide investigating docetaxel, docetaxel patients alone a of with and to stage dosing Phase of this recommended establishing the weeks. three of cancer, conjugate has treatment cytotoxic completed past THXXXX, the Currently, been the drug to

and could the neutralization rapid is April. cells, have docetaxel of cells, penetration of patients of alone. cancers. significant, significantly compared This specifically XX cancer along in a as We a as by THXXXX increased of to for cancer cancer This tumor to expect enable cells, administration cytotoxic therapeutic to more arm with the treatment differentiator of all key the targeted enrolled the of six drug agent within this the X.X as of is the THXXXX, delivery accumulation end times of

the dose XXX-milligram per DLT Phase or meter, square absence the become will if is dose. Now, toxicity recommended at this of X dose-limiting confirmed

immediately, larger and the trial once of open the The can which initiation safety start the further established, potentially May. of X will end as of will of basket enrollment begin the is discussed, dose tolerability early assess THXXXX. as trial, recommended Phase previously label As basket

other preliminary Sortilin XX are bone, questions solid enable that in was protocol to not breast An the We're amendment be the submitted. cancer, Sortilin is cancer, of that design deemed melanoma. a cell we show should One the addition, in breast to number accepted endometrial expect solid which received and FDA cancer, have tumor in any ovarian where before confident types, additional to additional we triple to deadline In does to following in expression will company date and XX for the submitted to receive and by happy half raised efficacy per tumors by to cancer expressing trial, for include amendments as responded the and potential the high. XX patients April the of FDA, the second negative hormone-positive basket arm to of X types high the be implemented. small the fibroid, Phase arm. was report total include XXXX, to to prostate, us patients will arm the has cancers given to selected date, be it added that questions protocol ready cancer,

partnering AACR cancer additional implications of cancers. therefore, important implications And conversations to ovarian recently CDXXX+ I've of around companies. the commercial signs China meeting, demonstrating the of of the Earlier Christian triple and second presented cells in carcinogenesis provide both cancers, early rights. the development of of importance at licensing an inhibition THXXXX new annual front, supporting our to breast color greater negative further development THXXXX’s investigation. pharmaceutical stem-like THXXXX’s posters the and attended the the in XXXX, a asked On for aid continues, biotech was different week, half in and have vivo considering and of rights the evaluation this human ongoing significant company cells Cancer efficacy presented, data. THXXXX what area number will three in are data commercialization with The the and preclinical in including in tumor and growth stem-like of expected

now. the calendar of previously to EGRIFTA the the XXXX. our formulation We supplemental noted for for file quarter to end by FX first intention tesamorelin DLA SV on Moving a of

by now we the recently companies’ the supplier or is make required resuming recently required that of available market. by of BWFI, shipment and modifications formulation, put facility before the restitution the for product. FDA, of Injection to to which Bacteriostatic inspected BWFI However, a Water also manufacturing noting that is was informed global FX and its is BWFI FDA for The were the notice its of sole out manufacturing shortage

of and all this supply result company's of related FX pause to have to activities decided formulation’s sBLA. submission a external As our Phase the interruption, chain NASH trial, delay we X

be NASH the was tesamorelin X formulation. may Phase the underpinned FX the you As company’s aware, by trial use of

certainty With source we've to the On and priority as no is are when the and resume seek manufacturing BWFI. initial of longer lifecycle management comment to activities, reliably can shipments normal. overhang get may for the around with a we start we tesamorelin BWFI to Phase indicate including learned note, can customers, BWFI, we on as that clinics, hospitals, positive scheduled that situation track high pharmacies, X which

FX in is note So, water confusion, there a want diluent which marketed the is used of no reconstitution to or currently we WFI, for as formulation. not Theratechnologies’ any injection to shortage different confer for that

commercialize by will determining unfortunate, an reviewing from and NASH interim that product. still circumstance continue development of program on refine for when we have demonstration partner, we plan towards the awaiting the can competitive unplanned alternative ideal our working a analysis, protocol we're this is to FDA take feedback through the Although and identifying and its financing our method amendment, that

the in Beyond fiscal our with to guidance, range XXXX this pipeline call, of of fiscal XX% when have and we commercial efforts, commercial reported full and we great for are This $XX in the XXXX, represents we go revenue which today's which to XXXX. business, want effect, we in aspirations $XX future. expecting for of growth million reiterate very proud year portfolio million in the to before the XXXX. our sales XX% be further fiscal $XX of And compared million for to range of

of emphasizing overall growth that XXXX through early With sales advancement objectives. achieving XXXX of our quarter. solid the operating full on weakest the sales of sales We our supported are sales to commercial into outlook, being plans, hired continue year, spite historically EGRIFTA the the internal we and to newly growing fact growth QX by in XX% our experience fiscal sales onboarding commercial XX% reinforce in commercial serve this by double digits force only blended SV will

the As breadth full expectation of which will by the fully sales should it deploy force, physicians we engagement of continue is restrictions, able once to exit April. our end the enabling that to be increased onboard, case our pandemic be we

the in particular diminish, performance, more the this now tier juncture, the future. is this of increase, the we backdrop our to recruitment of this and sales that an internal internal to engagement call. we’re expect building for at talents right force top As employee turnover of Against even convinced was continued allow function,

supplemental an the Trogarzo push IV HIV-X. application, US of biologics end for Drug filed at For with the treatment license Administration, the the FDA, company's was and XXXX sBLA of of mode Food for so the administration

With were patient which be Theratechnologies Prescription accordance Fee mode October with in Xrd, in administration a Drug TMB-XXX PDUFA a IM experience. formulation, and the intramuscular we Trogarzo the an are action TaiMed the The study. User date. drug’s improvement XXXX, will FDA given is accepting a also known approved, Act, our for within as the commonly evaluating of if filing, target marked of date

So, you milestones. before expecting in the the start next two summer of should season, months, be well the significant few

as trial. B THXXXX, X The Part the to first initiation of refer is trial basket of Phase the of or we what the

the in year-end is of objective. second full sales support our company's our sales The launch of force

turn to at of Philippe, the this introduce discuss the THXXXX preclinical summary our to Medical Officer period to will AACR who year. reporting financial Christian? data before would presented that I was Chief provide Now, I moving before over the to a Q&A, like call

Christian Marsolais

with presented. that drug belief SORTX AACR annual specifically peptide Thank everyone. wanted posters of morning, Theratechnologies that share ideal cancer the It the conjugates, you our for of we trafficking receptor some meeting, cells. into is and or good PDCs, you, and Paul. three candidate to attended findings were the an XXXX the is Hello

making common for As expression healthy cancer development. high is both target across background, attractive absent types, many in and an drug Sortilin it receptor tumor but tissues, almost known

with in grade poor is survival interestingly, and associated and Sortilin as number prognosis decreased function one rates four, tumor also of a typically expression, cancers. to of increases a

is oncology receptor. of the positive normal peptides Our SORTX platform consisting targeting SORTX technology an

payloads of PDCs, cells cellular currently for and traffic function technology peptide. shuttle by and pre-clinical where directly AACR, into of versatile their treatment with trafficking These technology the of function We potential native key cancer the specifically agents, this cancer of their increasing receptor anti-cancer decrease the cell at released the increase exploitation The to doxorubicin, its significant system. ratios is for specifically for drugs Sortilin in exciting peptide. presented of normal the the allows This flexible proprietary sparing is receptor-mediated order import-export as could efficacy a SORTX various in the ability and of pre-clinical concentration, cytotoxic that anti-cancer peptides to receptor by a from cancers. via in in The our platform is docetaxel, payload SN-XX, endosomal the the new involved cell, investigating conjugation demonstrate lysosomal to effect, are achieve into are attached combinations aspect the the PDC approach potentially search which in cytotoxic, lead strategies studies novel accomplished example, expressing to from This large as scavenger the to cells, authenticator of technology well-established platform data off-target drugs active different cancer peptide a exert like the toxicity. exploitation transmembrane the pathway, the inside cells. to of

Additionally, platform, Sortilin-positive it anti-cancer and the that in promise be different suggests effective trafficking targeting of Theratechnologies’ technology can payloads.

those also preclinical studies, in formation and as chemotherapy humans, conventional such indicated the stem as stem-like we are to are receptor radiotherapy. they carcinogenesis cells native and with conjugate, non-cancer SORTX In grow, vasculogenic cancer, CD-XXX, typically the that Moreover, we feed known resistance peptide into a to THXXXX mimicry the marker, associated From treatments. as an cells. our cancer are of cells of tumor the treatment demonstrated in moves bearing SORTX cancer cancer target contribute important cell investigated function. standard human part the they and study via is the stem treatments, stem-like structures of resistant to cancer, tumor of As also cancer to cell

to are breast cancer triple time that in Additionally, These of of tumor, clearly THXXXX is used the ovarian results cancer very first negative a The cancer, can ovarian or once have cytotoxic second efficacy the than the treatment. of induces stem cancer of impressive, we cell and for treatment. anti-cancer be as improve earlier for cancer can some patients compared that docetaxel- THXXXX in ovarian combination cancer. cells treatment. These alone are inside be effectively of better resistant opened both of in with to treatment more than and This presented the we carboplatin demonstrated THXXXX agent the as death in the carboplatin, standard and is combination certainly of that alone of stem-like showed results treatment. further the combinations results cancers. door treating lines THXXXX combination known a gold most these THXXXX to results the poster, carboplatin In ovaria the cells paclitaxel

showing at limiting equivalent murine results and tolerated rate cytotoxic mice in the demonstrate human technology, of is could models, therapeutic SORTX our AACR the metastasis. increased new resistant of drugs that confirm across xenograft agent. THXXXX to some optimizing tumor subcutaneous this the novel maximum melanoma able data platform results presented of THXXXX positive BXXF-XX better mice We shows dose that thereby to model THXXXX. XXX% summarize, the different were with the in that TCHXXXX. prolonged of toxicity, also survival inhibited well It delivery anti-cancer presented treated as be part poster of further window at third approach was that These the to demonstrated metastasis lung differentiators efficacy, in sustained novel and is a insightful cancers, against the cells, of the in that and doses improving efficacy as docetaxel also formation to and development therapeutic of regimens. key To established effective the Our THXXXX

effectiveness THXXXX First, especially docetaxel work, versus hard-to-treat in preclinical enhanced observed we alone, in refractory of have cancer.

those lastly, of to or concentration receptor as formation I Financial cancer of in of the BM to of fact with Philippe, And to expressions. target sparing the normal cytotoxic cancer cells, Second, Theratechnologies THXXXX cells, play growth and tenfold are dose SORTX in while little call inhibit a leveraging the mechanism be for to time, SORTX everyone. will cancer the to can behind X.X capacity Chief allow cells, the THXXXX cells Officer. Thank no known pass your at of action observation. agent you show stem-like could now

Philippe Dubuc

Thank at everyone. you, this reviewing that for the data Christian, presented we week morning, AACR, and good

over So, representing for the financials the turn the an for to three-month operator XX%. Q&A XXXX, million through revenues I'll year-ago call of compared XX, consolidated period, $XX.X ended the $XX.X February the was go session to million period the before I increase for same

in SV X.X%. selling America year, increase sold programs, QX rights. In an of XXXX, EGRIFTA The figure medical ended $X.X This increased same unit compared goods to were spending The XXXX, million R&D growth million in QX to For amortization to the increased was period higher of repurchase net Europe. compared our affairs sales. ‘XX, of the of North amounted as was In includes the both oncology $X.X sales the for goods in of net of last And Europe. $X million $X.X expenses to sales for same addition as related was for reflecting QX it fiscal to million mostly EGRIFTA spending spending reached last due to in education, representing million Selling of million America sold to to hires period. and $X.X well as amounted of greater to was increase in mainly compared the for amounted and medical by million largely commercialization million asset cost period Trogarzo while amortization higher intangible first of same in representing this cost and the increase to The fiscal Trogarzo in of sales included the quarter the activities in EGRIFTA year-ago is is rebates, growth $X.X year. as was XX%, commercialization QX for Europe. selling well increase in February combined year, XXXX. compared also - same million in patient $XX.X to of compared net Europe, in effect due cost sales a $X.X XXXX, both by higher impacted $X.X and $X.X as $X.X higher expenses XX, greater of the the and three-month of key commercialization price. the value a higher last year, in due quarter number million ‘XX, last and development sold, the territories. also million quarter units an expenses. of the first rights, North to of Revenue market

As increased and finance at the senior stable QX on $X.X Net ’XX, XXXX of costs in $XXX,XXX of were costs $X.X the quarter, last well G&A million last such, as in Europe. Net expenses million. activity ‘XX first $X.X QX mainly for included first associated million we in QX, the finance interest quarter finance in of comparable for accretion to notes recorded XXXX. year. well compared the with the in in for first last of as costs G&A in amounted in ‘XX, and an $XXX,XXX activities issued year, in include of QX $XXX,XXX expense June was increase business expenses The convertible quarter of QX year. in to compared Net ‘XX, expense period overall of an as also XXXX. in as first $XXX,XXX to quarter the in of increase

the $X XXXX, greater In to expense ’XX, due last net used three-month million in negative liabilities $X.X XX, same lower for year. in increase of $XX,XXX period million versus and increased and period February In XXXX, changes loss accounts positive positive accounts had was expenses revenues operating loss a impact And from above compared from compared expenses in cashflow to in prepaid and period increases from to the were for - as by the higher for first million offset year. the quarter and impacts lower the $X.X period of changes ended XXXX, fiscal million in the of in a operating assets decreasing Given the year's comparable $X.X impact on of these of activities receivable primarily included This greater last inventories deposits. and a QX QX million negative XXXX. payable. $X.X impact

So, we with ended million bonds, cash, and the funds. first fiscal $XX.X XXXX quarter of money in market

second off to revenues mentioned, just The expecting Paul million as is between And the we're quarter XXXX $XX confirm for good pleased million. to $XX guidance a XX, of start. fiscal and

Paul So, final the first, we'll call come with comments, Operator? back that, will with your take but questions. open to

Operator

of [Operator Capital. Uddin you. Our Instructions] from Andre question Mackie line Thank the coming with first Research

line Your is open.

Andre Uddin

thank Philippe, Okay, Morning, Christian. and you, Paul, operator.

Europe now, is in at how you terms plans European reps do those many Thank main looking have right sort Just for your your there focus countries? of are what of also, countries? where smaller and And commercial you.

Paul Levesque

Well, thank the you for question.

jurisdictions. So, a endeavor. know, pricing you That reimbursement. as that discussion much in many country-by-country is in not We've been Europe, endeavor an can obtain happen before with you is

an what very, medicine, because government a not negotiated were they positioning. from in the price, match But in to could have where very, the we We offering countries, not good accept what able price establish to forward And many a but country-by-country German we're wanted for in fairly reject still price the we a small consider that we would from and the acceptable that negotiation. had major believe European Italy, they aside negotiation. innovative offering that countries, been very we we it's drug to a put

second the France. are election as France their negotiation that in evolving. it's the currently midst in round round, We’re process. of to the Things going We through believe of going the is down slow first

us is important pool of the decisive. probably because So, country for an France patients significant. not April will is be But

clinical the activities as is very preparation So, have the we for in important market oncology. the Europe global and are story programs will And for in be resources that unfolding. updating our of meanwhile,

a Europe, of presence that pull Europe. to continuing in So, committed pricing is We're we a the trying matching having presence innovative this at have Trogarzo. time nature to and to we're best do in our

Andre Uddin

Okay that's useful.

of presented at some THXXXX preclinical data You AACR. nice

was in Thank Just going June. data we're you. it's see wondering ASCO if possible to if any at

Paul Levesque

Christian?

Christian Marsolais

earlier We Andre, is the the forward And need Yes. with any we three that the at to have we The go of abstract XXX. ASCO deadline this moment, following patients as the Paul at on we’re update this mentioned, activity three Then as was at for Andre. patients. submission June. in the the question. the potential we should as first the have communication towards for of that have patients year, Hello, year. that Thanks of mentioned, ASCO, XXX. were end but move the to in-human drug received won't in hoping, an on we

Andre Uddin

Okay. That's great. Thank you.

Paul Levesque

very, reassurance action, Christian we that what Thanks it is absolutely was for trial, your this innovative. just This move question. for putting And as play, of why mechanism its reason today with the exciting. because is we that presented Obviously, New an in week presented but find think on provides is at data, but see is we what forward emphasis I we'll extremely significant. basket we're what and Orleans pre-clinical it the believe is very this

question. Next

Operator

Kwai from of And our next line with National question Bank. the coming Stephen

line Your open. is

Stephen Kwai

been Hey I'm just the answered in taking question. guys, the calling for morning. most good opening and between remarks. had just have my my Thanks I and last of for questions actually questions Endri, one.

have and in been all China, strategy? partnership is negotiations Thanks. this some shutdowns at your there impacting given So,

Paul Levesque

of that moving set how is it not. you have It's companies are and frankly, than others. goes, No, faster you quite is ongoing, that know negotiation a

before too companies want in. let other don't conclude coming to you You fast

going of or as showing of I on interest I crew say, mix as increase. soon, into And or we keep pharma saying we're that the this biotechs to soon see we large So, think that to are frankly, quite have and would trial, a of, the is early early get to what sign as interest. we and is going nice, basket closer efficacy,

the quite many frankly, be CDA conducive getting under for with the getting right greater and great getting to will partner the with this So, actually right asset going, valuation China. conversation of them,

to are as plan when it So, the want that. anything? do per Philippe, moving you add things to comes

Philippe Dubuc

the the really is companies Well, from more or been we but that that’s thing usual. getting in feeling there's haven't only no, nothing pharmaceutical business biotech that than as China

So, any usual really talking there been for business It's to or hasn't impediments anything. them them. as to

Stephen Kwai

Thanks. all Okay, my great. Yes. That's questions.

Philippe Dubuc

Okay.

So, we have some questions on the - from the webcast.

So, from question that lead What its vitro for this manner function, in vivo seen your consistent previous concept around and is that out have a playing thus is a with humans Christian. you scientific and of discoveries? elements research you the that as in Sortilin would a believe in target, how in view far the to

Christian Marsolais

very consistent. a you impressive. data, question. always it's bit we've vitro in It's always the seen and to vivo, premature very Thank Yes. for terms in talk It's of the human about but in what

the first animal study. far profile have what terms in the the more but maybe safety reason efficacy, this docetaxel we safety, based we've of on Sortilin a the where I We of we and we XXX And number There's or have receptor. versus used recently we human, what mentioned, dose the increase DLT, normal inside is efficacy received some which were docetaxel, normal and are the expecting as of have cytotoxic using that per we with now times thus decreased like what of THXXXX concentration the And of seen X.X the seen And that similar of than see very dose that about milligrams two and of the are similar very like patients toxicity, similar is something to in significant would to that's why cycle. dose is that's DLT the because it's less haven't docetaxel. XXX. impressive. And the you patients don't good. cells. seen the cancer any human, And cell XXX to equivalent to remind cell early, doses three times lines see the in is square meter in expressing XXX, we a really we is for is

of on In if in the animal, when that shown what the and inside ratio docetaxel, seen in or four docetaxel the the the we times XX higher. the with of the moving cancer And addition, good times cells X.X we five or expecting can concentration program based be accumulation of we cancer before well. be Therefore, future. administered THXXXX, between the the in cytotoxic results is should cell, have We're dose times. at have the near X.X is

Philippe Dubuc

a track THXXXX. for with THXXXX regarding available window Next come approval question, Is opportunity there with of the revenue fast from accelerated any may that received designation?

Paul Levesque

for and This you good one. question. the question thank is an a So, interesting

that we within productive. Let reviewed treatment it the me expression THXXXX We and is strategic we reviewed guidelines THXXXX, results, can soon are Scientific try Mace data. as different be want a is to we to reviewed is indication? one and had our agency is, trial of an we obviously the individuals this indication platform to of can one because arms, high. know afterwards, as is accelerate all design we and need few do the in see the Member. Arena, really to pivotal And two really, treatment arsenal and we and these can forcefully developing knows will it's And on the provide we Rothenberg, we was color this what that play address plan about, can the that a the indications, and your a that Dr. for attended. one larger We with session, say, guidelines can extremely turn Christian, we but type fast-track time. oncology related the guidelines that the Joe with that an Board well. had Béliveau Advisor. could And rules, to we additional keep Our for understand had at we activity had We therapy orchestrated we the conducted to plan. recently with efficacy That at what it company that actually, time, of question indication you place to quite obviously It's is what to become somewhere trial to that sign the fastest something we exactly or early do which way frankly, designation SORTX one in an indications we actually tumor where where want squeeze within we treatment And not compelling a not predict least the cancer but deal. done this oncology at is you possible have this? applications so The in

Christian Marsolais

efficacy in to try with with will of plan some tumors, Well, And market get through so accelerated we far. those to FDA, of obtain number possible. are approved that path the number patients if no. of many with will recent there the like limited fast see where again, patients a FDA, examples we to as a design of years drugs with meet we in limited solid the signs were the a the and again, as That's

Philippe Dubuc

just patient - just There's a where the the enrollment expect we of on are and where in? we clarification the patients maybe the few dose. - six in a exactly around XXX-milligram be exactly the questions Can at you that on we when six clarify to are

Christian Marsolais

Yes.

any dose So, not of three far, as did XXX, at within treated cycle. before, our mentioned the XXX. DLT through Once we now treatment out were observe the we that lowered first Paul the patients

we in patients are be treated those April. three screened, think that will do patients and other The being

there no weeks patients that because three have DLT any be ready you DLT, we the April. And far, completed. confident certified that, will advanced, should should As but this patients three cycle XXX, the May that so will after are will to not be be experience with of - be if we're we in the there sometimes know, that do on the drug it's and of question. end initiate at trial, think based are the we be those treated difficult Then basket towards which

Philippe Dubuc

you how the question. or progress, the are planning NASH program please to progress? for to for Another Can you're you whether program NASH planning clarify

Paul Levesque

this we on I here, still in when amended it today. the comes the awaiting some speech but that the summarize me agency touched down let feedback the from So, protocol to presented. I elements We're think

would as on the analysis should amendment interim that We have the next this want few And submitted and within hard weeks, we data. wanted a from feedback we point to continue was with to we have said So, the you agency. recall, formal partnership.

analysis. So, we the that with could all how a different so of on and we can the non-dilutive interim start then at this looking in parallel conversation we're in are way trial partnership, also way execute front companies in and the we part to finance

to start We That with also prerequisite. a the will on that we when trial FX. that with We FX never carry you formulation. recall need started wanted the And is to were said decent that getting once share, a we to there will aspire extremely in things market were for three that the to market to plan, constituted our years important us come. trial be

formulations the to NASH Europe IP linked to but one in this America, to use right and IP the of is North the use tesamorelin NAFLD. have that and we in that the we linked FX case, It's in IP have two protection. things. linking And also patent in was First have the protection

So, but that that's means important, going and formulation. doesn't change, get FX need that with the to that we

to exactly the was of we've wide part The science wrong continue and to second and nothing behind there's the tesamorelin, mechanism and action that. with support what for have that's done,

our part and we if have actually we We to be in NASH. of ensure competitive. from having of anything, a win demonstration that was the have an trial tesamorelin, indication, we KOL support that chance mode the need And will say, to have once to a last complete brothered,

getting keep important. very, of That's be on competitive. very on will a method we working or a administration pen So, that

source all still as you still to forward together, this that the So, summarize, ongoing, I longer and again, feedback now serious to again, what unfortunately. global think if is that But my in moving no bacteriostatic and want water the and agency, amended we're stalling and the issue we now, speech, have that financing are slowly point, protocol be is hospitals list, to one this I surely. there I partnership, some this included and to us on shortage. is waiting able We'll put is the together visibility, all put other a And related now it from but the say stuff, associated all timeline we'll to able the but going batches to and financing? forward And we'll you NASH. maybe word and be the ourselves, with plan elements to then that. some are being the that what's manufacturing want at now manufacture Philippe, be decide to priority the released are of

Philippe Dubuc

Yes.

is convertible mentioned are in financing. bit but on of there's financing well. NASH for And over is few mention there interest away number maturity, address a still year that of that debenture the in non-dilutive also We a the that to times the starting questions before a blends of quite terms of as with Just, we it. a well,

And they at convert as in if same be in is will the were consideration want everything addressed someone the on non-dilutive to to time here. basis, so, Obviously, come well. taken a

whole one package. it's So,

So, that's for questions, Paul. the it

So, you can summarize then.

Paul Levesque

you, Philippe, our update Thanks, and thank joining everyone, and for Christian, call today.

data as year. that XXXX, on in commercial We conclusion, momentum that this on XX%, this particular, XX% of performance are today. our through well for year the sustain reviewed of SV the fiscal by very In have was the sales encouraged the for are growth the remainder commercial confirmed continues Christian quarter, signs early to the as greatly fiscal sales In we the in that to has call blended good built EGRIFTA of reported business. growth the

as the new presented side, a metastatic in key the seen promising differentiators is solid was AACR, as THXXXX, scientific cancers. Theratechnologies of On by data refractory at that novel therapy and

THXXXX alone, have hard-to-treat versus docetaxel enhanced Firstly, observed especially cancers. in effectiveness preclinical in refractory we of work,

receptors can THXXXX of the little normal known as mimicry concentration activities THXXXX cytotoxic cells, And behind with allow Second, to sparing stem-like to are cells, no inhibit of action tenfold agent, while fact show in target cancer expression. X.X of cells to those SORTX growth on to the SORTX a the to of leveraging vasculogenic those lastly, and of at formation mechanism capacity be observations. play cancer

unfortunate is it Additionally, manufacturing NASH that our in the development in FX component supply delayed chain program near-term. necessary of has the the

milestones, provided the from near-term the efficacy of However, us including second on THXXXX trial half the signs focused in this very a of of for basket early the reporting delay with to large completely opportunity of remain brink XXXX. has the

our We sales attention upmost force, will fully deliverance onboarding also our be provide in contribute of internal of which our able guidance will to to for the year.

we financing partners the these program move to necessary patient adherence registration NASH formulation. and execution forward, development seeking right new in significant strategy, of and taking initiation out the two Following mode to of milestones, utmost the optimized are experience reviewing our options, our alternative with including care the upcoming ensure to

forward across our attending, great full pipeline for advanced our necessary I update as the the clinic, progress hope this, our channels formulation. For forward we regulatory advance Thanks to Have our while we required revenue that continue everyone meet commercialize XXXX day, and for as to forecasted today, the a year, next to improved we with we an stage both aspiration to to product date move the markedly and expectations optimism navigating and able look and a call. have with guidance been with share commercial for to

Operator

participation. for does and gentlemen, your conclude today. you for our Ladies conference Thank that

may disconnect. You now

Theratechnologies (THTX) 13 Apr 222022 Q1 Earnings call transcript